Clinical Trials
25 trialsNCT05442515 2026-05-27
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05826535 2026-05-20
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT06564038 2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT02625480 2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2 Completed
NCT05702853 2026-03-27
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
Phase 1/2 Recruiting
NCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting
NCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04697940 2025-09-19
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
Phase 1/2 Active not recruiting
NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT07009002 2025-06-25
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06834529 2025-02-19
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Recruiting
NCT05201248 2025-01-07
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2 Active not recruiting
NCT03677141 2024-12-18
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT06002659 2024-05-09
CARMA-01
Uppsala University
Phase 1/2 Recruiting
NCT04715217 2023-12-29
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT05776407 2023-03-20
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
Phase 1/2 Unknown
NCT04030195 2023-01-31
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Precision BioSciences, Inc.
Phase 1/2 Completed
NCT03704714 2022-08-15
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Northwestern University
Phase 1/2 Suspended
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT03146533 2017-05-17
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Shenzhen Second People's Hospital
Phase 1/2 Unknown
NCT00634179 2016-10-27
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Emory University
Phase 1/2 Completed
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT00048737 2013-06-13
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00379574 2013-03-15
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Asan Medical Center
Phase 1/2 Completed